| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
CXCR3 (chemokine receptor 3). AMG 487 S-enantiomer is a CXCR3 antagonist.
|
|---|---|
| ln Vitro |
The S-enantiomer of AMG 487 is called compound 3.74, or AMG 487 S-enantiomer [1].
AMG 487 S-enantiomer is a potent antagonist of the chemokine receptor CXCR3. It is the S enantiomer of AMG 487. The compound is used to study CXCR3-dependent immune pathways. |
| ln Vivo |
No specific in vivo activity data is available for AMG 487 S-enantiomer. Researchers use AMG 487 (S-enantiomer) to study autoimmune diseases, transplant rejection, dermatitis, fibrosis, and T-cell-mediated inflammation. Its defined stereochemical potency and receptor specificity make it a valuable tool for exploring therapeutic strategies targeting CXCR3-dependent immune pathways.
|
| Enzyme Assay |
In vitro receptor binding assays for AMG 487 S-enantiomer involve measuring its affinity for CXCR3 using radioligand displacement or functional assays (e.g., calcium mobilization, chemotaxis assays). IC50 values are determined from dose-response curves. Selectivity is assessed by testing against other chemokine receptors.
|
| Cell Assay |
The in vitro cellular activity of AMG 487 S-enantiomer is evaluated in cells expressing CXCR3 (e.g., T cells, transfected cell lines). Cells are treated with the compound, and CXCR3-mediated signaling (calcium flux, chemotaxis, MAPK activation) is measured. The compound's ability to block CXCR3 activation by its ligands (CXCL9, CXCL10, CXCL11) is assessed.
|
| Animal Protocol |
No specific in vivo animal experimental protocols are available for AMG 487 S-enantiomer. For studying CXCR3 antagonism in disease models, the compound would typically be administered via intraperitoneal injection or oral gavage in rodent models of autoimmune diseases, transplant rejection, or fibrosis. Endpoints would include disease severity, immune cell infiltration, and cytokine profiles.
|
| ADME/Pharmacokinetics |
AMG 487 S-enantiomer has a molecular formula of C32H28F3N5O4 and a molecular weight of 603.59. LogP: 3.76. Solubility: DMSO: ~100 mg/mL (~165.68 mM). Storage: powder at -20degC for 3 years. In vivo formulation: 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline.
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for AMG 487 S-enantiomer. As a research compound intended for laboratory use, standard safety precautions should be observed. No clinical toxicity studies have been reported.
|
| References | |
| Additional Infomation |
AMG 487 S-enantiomer is the S-isomer of AMG 487, a potent antagonist of the chemokine receptor CXCR3. It is a valuable tool for exploring therapeutic strategies targeting CXCR3-dependent immune pathways in autoimmune diseases, transplant rejection, dermatitis, and fibrosis. It is not approved for clinical use.
|
| Molecular Formula |
C32H28F3N5O4
|
|---|---|
| Molecular Weight |
603.5910
|
| Exact Mass |
603.209
|
| CAS # |
473720-30-8
|
| Related CAS # |
AMG 487;473719-41-4;(±)-AMG 487;947536-03-0
|
| PubChem CID |
97992555
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
750.0±70.0 °C at 760 mmHg
|
| Flash Point |
407.4±35.7 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
3.76
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
44
|
| Complexity |
997
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
|
| InChi Key |
WQTKNBPCJKRYPA-NRFANRHFSA-N
|
| InChi Code |
InChI=1S/C32H28F3N5O4/c1-3-43-25-14-10-24(11-15-25)40-30(38-29-27(31(40)42)7-5-17-37-29)21(2)39(20-23-6-4-16-36-19-23)28(41)18-22-8-12-26(13-9-22)44-32(33,34)35/h4-17,19,21H,3,18,20H2,1-2H3/t21-/m0/s1
|
| Chemical Name |
N-[(1S)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~165.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (12.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6568 mL | 8.2838 mL | 16.5675 mL | |
| 5 mM | 0.3314 mL | 1.6568 mL | 3.3135 mL | |
| 10 mM | 0.1657 mL | 0.8284 mL | 1.6568 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
